Last reviewed · How we verify
Acute decompensated heart failure in patients receiving digoxin
Approved treatments
- Milrinone Lactate · Pfizer Inc.
Phosphodiesterase-3 inhibitor that increases cardiac contractility and promotes vasodilation through cAMP elevation.
Clinical guidelines
- FDA label — 1L
The majority of experience with intravenous milrinone lactate has been in patients receiving digoxin and diuretics. - FDA label — 1L
The majority of experience with intravenous milrinone lactate has been in patients receiving digoxin and diuretics.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute decompensated heart failure in patients receiving digoxin patent landscape — cliff calendar, originator estates, attackable patents
- Acute decompensated heart failure in patients receiving digoxin treatment landscape brief
- Acute decompensated heart failure in patients receiving digoxin treatment updates RSS
Frequently asked questions about Acute decompensated heart failure in patients receiving digoxin
What drugs treat Acute decompensated heart failure in patients receiving digoxin?
Tracked treatments include Milrinone Lactate.
What is the treatment for Acute decompensated heart failure in patients receiving digoxin?
Standard treatment for Acute decompensated heart failure in patients receiving digoxin includes Milrinone Lactate. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Acute decompensated heart failure in patients receiving digoxin?
FDA label publishes guidelines for Acute decompensated heart failure in patients receiving digoxin. 2 guideline references tracked.
Related
- Treatment landscape: Acute decompensated heart failure in patients receiving digoxin patent cliff · Acute decompensated heart failure in patients receiving digoxin CI report
- Treatment: Milrinone Lactate · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing